Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
Company Information
About this company
Key people
David A. Ricks
Chairman of the Board, President, Chief Executive Officer
Jacob S. Van Naarden
Executive Vice President, President - Lilly Oncology
Juan Ricardo Luciano
Lead Independent Director
Ralph Alvarez
Independent Director
Katherine Baicker
Independent Director
Carolyn R. Bertozzi
Independent Director
J. Erik Fyrwald
Independent Director
Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Eric Dozier
Executive Vice President, Chief People Officer
Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Daniel M. Skovronsky
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Anat Hakim
Executive Vice President, General Counsel, Secretary
Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Melissa Seymour
Executive Vice President - Global Quality
Click to see more
Key facts
- Shares in issue943.36m
- EPICLLY
- ISINUS5324571083
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$855.34bn
- Employees50,000
- ExchangeNew York Stock Exchange
- IndexS&P 500, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.